| abstract |
The present invention relates to chimeric polypeptides in which serum albumin protein has been altered to contain one or more biologically active heterologous peptide sequences. The chimeric polypeptide will exhibit therapeutic activity related to heterologous peptide sequences associated with an improved serum half-life obtained from serum albumin protein fragments. The heterologous peptide sequence may be selected to promote some biological effect, including angiogenesis inhibition, antitumor activity, and induction of apoptosis. The therapeutic effect may be achieved by direct administration of the chimeric polypeptide or by transfecting cells with a vector containing a nucleic acid encoding such a chimeric polypeptide. |